Using the nanopore-based molecular sensing technology developed by Oxford Nanopore, Mayo Clinic researchers can develop new clinical tests to sequence a patient’s DNA and examine methylation — a biochemical process that regulates gene expression — in real time, according to an Oct. 19 news release.
Typically, examining methylation is a separate process that requires additional time and cost. The ability to do this in real-time will allow clinicians to see a more complete picture of a patient’s cancer genome.
The partnership ultimately “further helps advance patient care,” Bobbi Pritt, MD, the interim chair of Mayo Clinic’s Department of Laboratory Medicine and Pathology, stated in the release.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
